ANADIS SPRAY ‘SWITCHES-OFF’ MOUSE INFLUENZA VIRUS REPLICATION
August 22nd 2008 22:33
Wednesday August 20, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS UP: PEPLIN UP 19%, CYTOPIA DOWN 17%
* ANADIS SPRAY ‘SWITCHES-OFF’ MOUSE INFLUENZA VIRUS REPLICATION
* PHARMAXIS STUDY SHOWS BRONCHITOL ‘SAFE’ AFTER 12 MONTHS
* VIRALYTICS PHASE I CANCER TRIAL 2nd DOSE COMPLETED; 3rd TO GO
* ADVANCED SURGICAL POSTS $190k PROFIT ON REVENUE UP 21.5%
* IMUGENE: ‘PRRS VACCINE SUCCEEDS IN PIG TRIAL’
* BIODIEM, GENZYME DEVELOP BDM-E SCALE-UP
* AVANTOGEN PROMISED $1m OF $3m PLACEMENT
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
ANADIS
Anadis says its cow colostrum nasal antibody spray for immediate post-exposure prophylaxis against a range of influenza viruses is effective in mice.
The University of Melbourne’s Department of Microbiology and Immunology has completed a series of proof-in-principal experiments based on mouse influenza challenge models.
The experiments conducted by Prof Loreena Brown used an animal model designed specifically to test influenza prevention and treatment and demonstrated the ability of the antibody spray to “switch-off” virus replication in the respiratory tract lining.
Anadis said its polyclonal antibodies were obtained by vaccinating dairy cows and collecting first-milking colostrum where it was then formulated as a spray dried powder, for later reconstitution as a natural nasal spray.
The studies indicated a significant impact of single and daily dose of the Anadis polyclonal antibodies in reducing the likelihood of infection and reducing the severity of those infected with influenza.
Anadis said its team and University of Melbourne scientists would submit their data for publication and intended to present the details at an influenza control conference.
Anadis’ chief executive officer Dr Zeil Rosenberg said the topical spray approach to protecting individuals during seasonal or epidemic flu outbreaks was “a radical new paradigm to protect people from these influenza viruses”.
“The fact that the Anadis antibodies are all natural and topically applied means we may have a very safe and effective new approach to provide immediate protection to all persons and be able to address multiple virus strains,” Dr Rosenberg said.
He said that current failures in vaccine protection this year showed that new approaches like Anadis’ spray were urgently needed.
Anadis was up 0.3 cents or four percent to 7.8 cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 21 |
| Vote |
Shared on
Add To: 
Subscribe to this blog
